Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain

Study:

A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain

Rationale:

n/a

Purpose:

To determine the safety and efficacy of SNX-111 in controlling severe, chronic pain in cancer and AIDS patients.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
HIV Infections
Cancer
Pain
Drug: Ziconotide Phase 2

Verified by Neurex March, 1998

Sponsored by: Neurex
Information provided by: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov identifier: NCT00002160

Study Type: Interventional

Study Design: Treatment, Double-Blind, Safety Study

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site